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LiverHepatic ischemia/reperfusion (I/R) injury can arise as a complication of liver surgery and transplantation. Sirtuin
1 (SIRT1), an NAD+-dependent deacetylase, modulates inﬂammation and apoptosis in response to oxidative
stress. SIRT1,which is regulated by p53 andmicroRNA-34a (miR-34a), canmodulate non-alcoholic fatty liver dis-
ease, ﬁbrosis and cirrhosis. Since carbon monoxide (CO) inhalation can protect against hepatic I/R, we hypothe-
sized that CO could ameliorate hepatic I/R injury by regulating the miR-34a/SIRT1 pathway. Livers from mice
pretreatedwith CO, or PFT, a p53 inhibitor, displayed reduced production of pro-inﬂammatorymediators, includ-
ing TNF-α, iNOS, interleukin (IL)-6, and IL-1β after hepatic I/R injury. SIRT1 expression was increased by CO or
PFT in the liver after I/R, whereas acetylated p65, p53 levels, and miR-34a expression were decreased. CO in-
creased SIRT1 expression by inhibiting miR-34a. Both CO and PFT diminished pro-inﬂammatory cytokines pro-
duction in vitro. Knockdown of SIRT1 in LPS-stimulated macrophages increased NF-κB acetylation, and
increased pro-inﬂammatory cytokines. CO treatment reduced miR-34a expression and increased SIRT1 expres-
sion in oxidant-challenged hepatocytes; and rescued SIRT1 expression in p53-expressing ormiR-34a transfected
cells. In response to CO, enhanced SIRT1 expression mediated by miR-34a inhibition protects against liver dam-
age through p65/p53 deacetylation, which may mediate inﬂammatory responses and hepatocellular apoptosis.
The miR-34a/SIRT1 pathway may represent a therapeutic target for hepatic injury.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatic ischemia–reperfusion (I/R) injury is a major cause of liver
dysfunction that occurs as the result of resuscitation from hemorrhagic
shock or surgical procedures such as liver transplantation and liver re-
section. The initial hepatic injury during I/R results from increased reac-
tive oxygen species (ROS) production, which can promote apoptosis
and acute inﬂammatory responses. Inﬂammation during I/R can lead
to endothelial and Kupffer cell activation and cytokine/chemokine re-
lease associated with increased hepatocyte cell death [1,2]. During I/R
injury, activation of Toll-like receptor 4 (TLR4)-dependent innate im-
mune mechanisms can promote liver damage through the increase ofL2-associatedX protein; CO, car-
ules; I/R, ischemia/reperfusion;
thrin-α p-nitro; SIRT1, sirtuin 1
ces, University of Ulsan, Ulsan,
82 52 259 2740.
. This is an open access article underpro-inﬂammatory cytokines, and can lead to chronic inﬂammation
and disease [3].
Carbonmonoxide (CO), a reaction product of heme oxygenase (HO)
activity, can exert potent anti-inﬂammatory, anti-proliferative, and
anti-apoptotic effects in vitro and in vivo and thereby mimic the
cytoprotective effect of HO-1 [4–6]. Tissue protective effects have been
described in organ transplantation models after perfusion with exoge-
nous CO, resulting in graft preservation [6–9]. Furthermore, exogenous-
ly applied CO can ameliorate I/R injury in animal models through anti-
inﬂammatory, vasodilatory, and antiapoptotic effects [10–14]. However,
the molecular mechanisms underlying the protective effect of CO in I/R
injury have not been well elucidated.
Sirtuin 1 (SIRT1) is an NAD+-dependent deacetylase implicated in
diverse cellular processes, including metabolism, development, stress
response, neurogenesis, inﬂammation and apoptosis [15–17]. SIRT1
can act as a robust metabolic protector in several systems, including
the liver, brain and immune system [18]. Recent studies indicate that
SIRT1 can downregulate inﬂammatory responses in various models
[19–23]. For example, SIRT1 was linked to protection from diabetes
and steatosis through reduction of the inﬂammatory response,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SIRT1 can protect the heart and brain from I/R injury, and ameliorate in-
ﬂammation and apoptosis in these models through NF-κB/p65 and p53
deacetylation [24,25]. SIRT1 expression in the liver is speciﬁcally regu-
lated by microRNA-34a (miR-34a) [26,27]. Targeting of the miR-34a/
SIRT1/p53 pro-apoptotic pathway increased SIRT1 expression, de-
creased acetylation of p53, reduced apoptosis in primary hepatocytes,
and also reduced steatosis in vivo [28,29].
On the basis of these observations, we hypothesized that induction
of SIRT1 by CO-mediatedmiR-34a inhibition could play a role in amelio-
rating hepatic I/R injury. To test this hypothesis, we used CO inhalation
or application of piﬁthrin-α p-nitro, a p53 inhibitor, as therapeutic in-
terventions for experimental hepatic I/R injury in mice. We demon-
strate that induction of SIRT1 by CO-dependent miR-34a inhibition
decreases I/R-induced inﬂammatory responses and apoptotic hepatic
injury via SIRT1 deacetylase activity acting on NF-κB/p65 and p53.
Thus, we identify a novel mechanism for CO action, as well as a thera-
peutic target for hepatic I/R injury.
2. Materials and methods
2.1. Chemicals and reagents
Tricarbonyl dichlororuthenium (II) dimer (CORM-2), piﬁthrin-α p-
nitro, hydrogen peroxide (H2O2), EX527 as a SIRT1 inhibitor, and lipo-
polysaccharide (LPS) (055:B5) were purchased from Sigma-Aldrich
(St. Louis, MO, USA).
2.2. Animals
Male C57BL/6 wild-type (WT) mice were used at 6–8 weeks of age
(Orient Bio, Seoul, South Korea). Animals were maintained in a speciﬁc
pathogen-free facility. Animal studies were approved by the University
of Ulsan Animal Care and Use Committee.
2.3. Cell culture
The murine macrophage cell line, RAW 264.7 was maintained in
DMEM. AML12mouse hepatocytes (ATCC; CRL-2254) were maintained
in DMEM/F12. All media were supplemented with 10% fetal bovine
serum (FBS) and a 100 units/ml penicillin/streptomycin mixture
(Gibco, Grand Island, NY). Cell lines were incubated at 37 °C with
100% humidity in 5% CO2 and passaged using standard cell culture
techniques.
2.4. Isolation of primary hepatocytes and Kupffer cells (KCs)
Primary hepatocytes and Kupffer cells were isolated from mice by
collagenase digestion and by the two-step Percoll gradient method
with slight modiﬁcations. Mice were anesthetized, and the peritoneal
cavity was opened. Livers were perfused with Ca2+ and Mg2+-free
Hank's buffered salt solution (HBSS) (Gibco) containing EGTA
(2.5 mM) and then digested with a collagenase buffer containing colla-
genase (0.5 mg/ml, C5138, Sigma), NaCl (66.7 mM), KCl (6.7 mM),
HEPES (50 mM), and CaCl2 (4.8 mM). Digested livers were dissected
and then gently teased with forceps until they were in solution. The
cell suspensions were ﬁltered through a 100-μm nylon cell strainer
(BD Falcon). The cellswere centrifuged for 5min at 1900 rpmand resus-
pendedwithHBSS. After the cell suspensionswere centrifuged for 3min
at 450 rpm, the supernatants (non-parenchymal cells such as Kupffer
cells) were transferred to a new tube, and the pellets (parenchymal
cells such as hepatocytes) were resuspended with HBSS.
For Kupffer cell isolation, the supernatants were layered onto a 50/
25% two-step Percoll gradient (GE Healthcare, Uppsala, Sweden) for
15 min at 3200 rpm with the brake option off. KCs in the middle layer
were collected and washed with DMEM supplemented with 10% FBS.One hour following seeding, non-adherent cells (cell debris and blood
cells) were removed by replacing the culture medium. The purity of
KCs was conﬁrmed by ﬂow cytometry using PE-conjugated anti-F4/80
Antibody (BM8) (eBiosciences, SanDiego, CA, #12-4801-82). Flow cyto-
metric analysis was performed using a FACSCanto II (BD) cytometer,
and data were analyzed using FACSDiva software (BD Biosciences)
and FlowJo software (TreeStar, Ashland, OR).
For hepatocyte isolation, the pellet suspensions obtained as de-
scribed above were centrifuged using 25% Percoll for 5 min at
800 rpm with the brake option off. The pellets were washed with
DMEM supplemented with 10% FBS, and then cells were seeded into a
collagen pre-coated 100 mm tissue culture plates. After 24 h, non-
adherent cells were removed by aspiration, and fresh media were
added.
2.5. Carbon monoxide treatment
To evaluate the protective effect of inhaled CO,mice inhaled CO at 250
parts permillion (ppm) in air (Core Gas, Ulsan, South Korea) for 12 h in a
sealed exposure chamber (LB Science, Daejeon, South Korea) prior to the
experiment. Mice were placed in an exposure chamber (LB Science) at
room temperature for exposure to air (control) or to 250ppmCOasmon-
itored by a CO probe (Tongoy Control Technology, Beijing, China). During
reperfusion, mice were exposed to CO (250 ppm) for 6 h.
2.6. Mouse liver I/R injury model
We used a well-established mouse model of warm hepatic ischemia
followed by reperfusion [30]. An atraumatic clip was used to interrupt
the arterial/portal venous blood supply to the cephalad liver lobes.
After 60min the clip was removed andmicewere sacriﬁced after reper-
fusion. Sham wild-type (WT) controls underwent the same procedure,
but without vascular occlusion. Mice were exposed to compressed air
or CO. CO or room air was given to the mouse overnight prior to the
liver ischemia and during reperfusion. In some experiments, mice
were treated with a p53 inhibitor, piﬁthrin-α p-nitro (2.2 mg/kg, [29])
or the vehicle DMSO, three times for 1 week prior to ischemia.
2.7. Hepatocellular damage assay
To detect serum alanine aminotransferase (ALT), serumwas collect-
ed from peripheral blood. ALT activity, an indicator of hepatocellular in-
jury, was measured using the EnzyChrom™ Alanine Transaminase
Assay Kit (BioAssay System, Hayward, CA).
2.8. Liver histology
For histopathological observations, portions of liver were ﬁxed in
10% neutral-buffered formalin solution and then dehydrated in graded
alcohol. The ﬁxed tissue was embedded in parafﬁn and sliced into
4-μm-thick sections. Tissue sections were mounted on regular glass
slides, deparafﬁnized in xylene, rehydrated in decreasing concentra-
tions of ethanol, and stainedwith hematoxylin and eosin (H&E). Overall
pathological changes, including immune cell inﬁltration, and hepatic
cell necrosis were diagnosed according to previously described
methods [31].
2.9. Immunohistochemistry
For the detection of SIRT1, F4/80, and LY6G by immunohistochemis-
try, SuperPicTureTM Polymer Detection Kit Invitrogen Polymer Detec-
tion System (Invitrogen, Frederick, MD, #879663) was used according
to the manufacturer's protocols. Brieﬂy, after administrating Peroxo-
block solution (Invitrogen, #002015), the sections were incubated ﬁrst
with anti-SIRT1 (Santa Cruz Biotechnology, Santa Cruz, CA, #15404,
1:100 dilution), anti-F4/80 (Abcam, Cambridge, MA, #6640, 1:100
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night incubation, the sections were washed and then incubated with
HRP polymer conjugate. Tissue sections were visualized with the sub-
strate DAB chromogen (diaminobenzidine); and then the sections
were then counterstained with hematoxylin.
2.10. Myeloperoxidase (MPO) activity assay
Neutrophil sequestration in liverwas quantiﬁed bymeasuring tissue
MPO activity. Tissue samples for MPO analysis were frozen in liquid ni-
trogen immediately after removal from the animal and were thawed
and homogenized and centrifuged to remove insoluble materials. MPO
levels were measured using a mouse myeloperoxidase DuoSet ELISA
kit (R&D Systems, Minneapolis, MN) according to the manufacturer's
instructions. The supernatants were analyzed for MPO levels by ELISA.
The levels ofMPO in organ extracts were expressed as ng/mg of protein.
2.11. Transfection of plasmids, miRNAs and siRNAs
The p53 responsive element reporter plasmid (p53-luc) was pur-
chased from Stratagene (La Jolla, CA). A pRL-SV40 Renilla luciferase con-
struct was purchased from Promega (Madison, WI). pCMV-p53WT
(containing human wild-type p53) was purchased from Clontech
(Mountain View, CA) (631922). WT-SIRT1 3′UTR constructs were
fromAddgene (Cambridge,MA) (Addgene plasmid 20379). Small inter-
fering RNAs (siRNAs) against SIRT1 (SIRT1-siRNA) (sc-40987) and con-
trol siRNA (scRNA) (sc-37007) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). MicroRNAs (miRNAs) against miR34a
(miRIDIAN microRNA Mouse mmu-miR-34a-5p-mimic, C-310529-07
and meridian microRNA human has-miR-34a-5p-mimic, C-300551-
07) and control miRNA (meridian microRNA mimic Negative Control,
CN-001000-01)were purchased fromThermoPierce Biotechnology Sci-
entiﬁc. Cells were transfected with plasmids, siRNAs, andmiRNAs using
Lipofectamine 2000 reagent (Life Technologies, New York, USA) and
Hiperfect transfection reagent (QIAGEN, Valencia, CA). After 36 h of
transfection, cells were harvested for RT-PCR, immunoblotting, or lucif-
erase assay.
2.12. Luciferase assay
AML12 cells were transiently transfected with the ﬁreﬂy luciferase
reporter plasmids and the Renilla luciferase-expressing plasmid (pRL-
SV40; Promega, Madison, USA), the latter as a transfection control,
were transiently transfected into AML12 cells using Lipofectamine
2000 reagent (Life Technologies). After 36 h of transfection, cells were
harvested and lysed with 100 μl of cell culture lysis buffer (CLB,
Promega). Lysates of the transfected cells were analyzed using the
dual luciferase assay kit (Promega) according to themanufacturer's pro-
tocol. The luciferase activities were measured on a SpectraMax L (Mo-
lecular Devices, Sunnyvale, CA). Fireﬂy luciferase activity of p53-luc
andWT-SIRT1 3′UTRwere normalized to Renilla luciferase in each sam-
ple. Each experiment was carried out at least three times with triplicate
samples.
2.13. Quantitative RT-PCR analysis
Total RNAwas prepared using Trizol reagent (Invitrogen). Threemi-
crogram of total RNA was used to synthesize the ﬁrst-strand cDNA by
using oligo-dT primers (QIAGEN) and M-MLV reverse transcriptase
(Promega) according to the manufacturer's instructions. The synthe-
sized cDNA was subjected to the PCR-based ampliﬁcation. Semi-
quantitative RT-PCR was performed using Taq polymerase (Bioneer,
Daejeon, South Korea). Real-time PCR was performed using SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA) on an ABI
7500 Fast Real-Time PCR System (Applied Biosystems). Real-time PCR
primer pairs were as follows: TNF-α: 5′-AGA CCC TCA CAC TCA GATCAT CTT C-3′, 5′-TTG CTA CGA CGT GGG CTA CA-3′, IL-6: 5′-CGA TGA
TGC ACT TGC AGA AA-3′, 5′-TGG AAA TTG GGG TAG GAA GG-3′; IL-
1β: 5′-TCG CTC AGG GTC ACA AGA AA-3′, 5′-ATC AGA GGC AAG GAG
GAA ACA C-3′; iNOS: 5′-ACT GTG TGC CTG GAG GTT CT-3′, 5′-TCT CTG
CCT ATC CGT CTC GT-3′; CXCL10: 5′-TTT TCT GCC TCA TCC TGC TG-3′,
5′-CCT TTC AGA AGA CCA AGG GC-3′; GAPDH: 5′-GGG AAG CCC ATC
ACC ATC T-3′, 5′-CGG CCT CAC CCC ATT TG-3′; SIRT1: 5′-CAG ACCCTC
AGG CCA TGT TT-3′, 5′-ACA CAG AGA CGG CTG GAA CT-3′. mRNA ex-
pression data were normalized to GAPDH gene expression. The nucleo-
tide sequences of the primers used for semi-quantitative RT-PCR are
listed in Table S1.
2.14. MicroRNA analysis
Total RNAwas isolatedwith Trizol reagent (Invitrogen). RNAwas re-
verse transcribed using themiScript Reverse Transcription kit (QIAGEN)
according to the manufacturer's instructions. A quantitative PCR was
performed using amiScript SYBR-Green PCR Kit (QIAGEN) andmiScript
Primer assays for miR-34a (MS00001428, QIAGEN), with RNU6B
(MS00033740, QIAGEN) used as an internal control, according to the
manufacturer's protocol. miRNAs were detected using ABI 7500 Fast
Real-Time PCR System (Applied Biosystems) by monitoring in real-
time the increase in ﬂuorescence of SYBR Green detection.
2.15. Western blot analysis
Harvested liver tissues and cells were lysed with mammalian lysis
buffer containing phosphatase and protease inhibitors. Equal amounts
of cell lysates wasmeasured with the BCA protein assay reagent (Pierce
Biotechnology, Rockford, IL). Lysates were boiled in sample buffer con-
taining β-mercaptoethanol for 5 min. Proteins were then subjected to
SDS-PAGE and transferred to polyvinylidene diﬂuoride membranes
(GE healthcare). After blocking with 5% skim milk in PBS, membranes
were incubated with appropriate dilutions of antibodies at 4 °C
overnight as follows: polyclonal rabbit anti-SIRT1 (Millipore, Temecula,
CA, #07-131, 1:3000 dilution), rabbit anti-acetylated p65 (Abcam,
#52175, 1:1000 dilution), acetylated p53 (Cell Signaling Technology,
Danvers, MA, #2570, 1:1000 dilution, Bcl-2 (Cell Signaling, #2876,
1:1000 dilution), Bcl-XL (Cell Signaling, #2764, 1:1000 dilution),
cleaved caspase-3 (Cell Signaling, #9661, 1:1000 dilution), and Bax
(Santa Cruz, #526, 1:1000 dilution) and β-actin (Santa Cruz, #1616,
1:1000 dilution) were used. Membranes were then washed with
0.05% PBS–Tween 20 and incubated with a 1/5000 dilution of HRP-
conjugated secondary Abs at room temperature for 1 h. Immunoreactiv-
ity was detected using the ECL detection system (GE Healthcare). Films
were exposed at multiple time points to ensure that the images were
not saturated.
2.16. Statistical analysis
All data were expressed as mean ± SD. Differences between exper-
imental groups were compared using the Student's two-tailed unpaired
t-test.
3. Results
3.1. Carbon monoxide protects against liver ischemia/reperfusion injury in
mice
CO has been shown to exert protective effects in various tissue
models of I/R injury [7,11–14,32].We therefore analyzed the effect of in-
haled CO on hepatocellular function in mice subjected to 60 min of
warm ischemia followed by 6 h of reperfusion. As shown in Fig. 1A,
serum ALT levels in mice subjected to hepatic I/R were decreased in an-
imals pretreated with CO gas (250 ppm), as compared with room air
(2688 ± 1054 vs. 8561 ± 3185 U/L respectively, P b 0.01). Likewise,
Fig. 1. Carbon monoxide protects against liver ischemia/reperfusion injury through induction of SIRT1 in mice. Mice were sham-operated or subjected to 60 min liver warm ischemia
followed by 6 h of reperfusion. Mice were treated with air or CO gas (250 ppm) inhalation. (A) sALT levels (U/L) were measured in blood samples retrieved after I/R. (B) Liver neutrophil
accumulationwas assessed byMPO level. (C)H&E stainingof liver samples fromair- andCO-inhaledmice after hepatic I/R or sham treatment. (D) Immunohistochemical staining for F4/80
and Ly6G in the liver tissue was performed. (E) The gene expression of TNF-α, IL-6, iNOS, and IL-1βwas evaluated in liver tissue by quantitative RT-PCR. (F) Hepatic expression of SIRT1,
acetylated-p65, cleaved-caspase-3 and p65 were evaluated in IR lobes from air- and CO-inhaled mice by immunoblotting. β-Actin was used as an internal control. (G) SIRT1 mRNA ex-
pression was as detected by quantitative RT-PCR in liver tissue. (H) Immunohistochemical staining of SIRT1 was performed on liver sections. (I) qRT-PCR analysis of miR-34a expression
in liver tissue. miR-34a expression data were normalized to RNU6B. Data shown represent the mean ± SD. (N = 4–6/group), ***P b 0.001, **P b 0.01.
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cumulation, was depressed in mice that inhaled CO, compared with the
air-inhalation control group after hepatic I/R (4.026± 1.173 vs. 9.034±1.952 ng/mg, respectively, P b 0.01) (Fig. 1B). Moreover, histological ex-
amination of the liver from CO-pretreated mice revealed reduction of
the typical lesions of hepatocellular necrosis and sinusoidal congestion
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function of CO, ﬁrst we detected inﬂammatory cell inﬁltration and
then analyzed the expression of hepatic cytokines. In order to investi-
gate inﬂammatory cell inﬁltration, we performed immunohistochemi-
cal staining for Ly-6G and F4/80 (Fig. 1D). The increase of inﬁltrated
cells after surgery was reduced by CO inhalation. Consistent with the
immunohistochemical data, the mRNA levels of iNOS and pro-
inﬂammatory cytokines (i.e., TNF-α, IL-6, and IL-1β) were signiﬁcantly
decreased in the livers of mice subjected to hepatic I/R with CO inhala-
tion, compared to those of the air inhalation group (Fig. 1E). These ﬁnd-
ings suggest that CO inhalation can ameliorate I/R injury in the liver.
3.2. The protective effect of CO in hepatic I/R injury is associated with SIRT1
induction
SIRT1 can protect against I/R injury in heart and brain tissue [24,25].
Previous studies suggest that p53 acts as a transcription factor to in-
crease the expression of miR-34a which in turn regulates SIRT1 [27,
33]. In addition, it was reported that HO-1 can reduce miR-34a expres-
sion [34]. To evaluate the potential role of SIRT1 in CO-mediated liver
protection, we analyzed the effects of CO on SIRT1 expression in vivo.
As shown in Fig. 1F, the expression of SIRT1 inmice subjected to hepatic
I/R injury and receiving air-inhalation pretreatment was increased
when compared with the sham I/R group. Interestingly, mice subjected
to CO inhalation pretreatment revealed a markedly increased SIRT1 ex-
pression in the liver after hepatic I/R, compared with the sham control,
and air inhalation control mice. Induction of SIRT1 in CO-treated mice
was also associated with decreased acetylation of the p65 subunit of
NF-κB, and the decreased expression of the cleaved form of caspase-3
(Fig. 1F). Consistent with Western blot data, the expression of SIRT1
mRNA was dramatically increased in CO-pretreated mice subjected to
hepatic I/R, whereas it was not altered in the other treatment groups
(Fig. 1G). Next, to conﬁrm these results, we performed immunohisto-
chemical staining which clearly showed increased SIRT1 expression in
CO pretreated mice during hepatic I/R (Fig. 1H). We also examined the
effect of CO on the miR-34a signaling pathway in vivo, which is known
to regulate SIRT1. As shown in Fig. 1I, miR-34a expression was de-
creased in the CO-inhalation I/R group when compared with I/R mice
subjected to air inhalation. These results, taken together suggest that
SIRT1 induction following CO inhalation was associatedwith the reduc-
tion of miR-34a expression.
3.3. p53 inhibition confers functional protection against I/R injury in mice
We observed that inhalation of CO reducedmiR-34a expression in I/
R-treated mice in association with tissue protection. We hypothesized
that this may be due to reduction of p53 transcriptional activity. Inhibi-
tion of p53 can reduce endotoxemic liver injury and protect against the
apoptotic response after renal I/R [35,36]. Therefore, we analyzed the ef-
fect of the p53 inhibitor, piﬁthrin-α (PFT), on hepatocellular function in
mouse liver subjected to 60 min of warm ischemia followed by 4 h re-
perfusion. As shown in Fig. 2A, sALT levels were decreased in mice
pretreated with PFT as compared with vehicle (DMSO)-treated mice
(1481± 53 vs. 2112 ± 165 U/L respectively, P b 0.01). Liver MPO activ-
ity was decreased in mice pretreated with PFT, compared to vehicle-
treated mice (5.696 ± 2.294 vs. 8.884 ± 0.735 ng/mg, respectively,
P b 0.05) (Fig. 2B). Additionally, we found that PFT reduced hepatocellu-
lar necrosis and sinusoidal congestion as well as attenuated the expres-
sion of HMGB1, an inﬂammatory cytokine that can promote liver
damage following I/R injury (Fig. 2C–D). Moreover, to assess the immu-
noregulatory function of p53, we studied hepatic cytokine/chemokine
expression patterns. Consistent with the results for liver damage by
H&E staining (Fig. 2C), the mRNA levels of pro-inﬂammatory mediators
such as TNF-α, IL-6, IL-1β, iNOS and CXCL10 were signiﬁcantly de-
creased in the liver of mice subjected to PFT administration, comparedwith those of the control group (Fig. 2E). Collectively, these results indi-
cate that inhibition of p53 has a protective effect in hepatic I/R.
3.4. p53 inhibition induces SIRT1 expression after hepatic ischemia/
reperfusion
To assess whether attenuation of hepatic I/R injury by p53 inhibition
is due to SIRT1 induction, we tested the effect of PFT on SIRT1 expres-
sion. Treatment ofmicewith PFT duringhepatic I/R increased SIRT1 pro-
tein andmRNA levels when comparedwith the untreated sham I/R and
vehicle control groups (Fig. 2F and G). In contrast, miR-34a expression
was decreased in the presence of PFT (Fig. 2H). In addition, induction
of SIRT1 was also associated with decreased acetylation of p65
(Fig. 2F). Taken together, these results suggest that SIRT1 induction fol-
lowing PFT injection was associated with decreased expression of miR-
34a as the consequence of the inhibition of p53 transcriptional activity.
Because SIRT1 can also catalyze the deacetylation of p53, we further
performed immunoblot analysis to determine whether the protective
effect of SIRT1 induction by PFT during hepatic I/R injury depends on
p53 deacetylation. We found that PFT injection diminished the levels
of acetylated p53 and cleaved caspase-3; whereas, it increased the ex-
pression of antiapoptotic Bcl-2/Bcl-XL proteins in the liver of mice sub-
jected to hepatic I/R, compared with the DMSO-injected group
(Supplementary Fig. 1). These ﬁndings demonstrate that inhibition of
p53 transcriptional activity by PFT suppresses the apoptotic pathway
in association with increased SIRT1 deacetylase activity.
3.5. Carbon monoxide reduces inﬂammation through SIRT1 induction in
macrophages
Previous reports have shown that SIRT1 acts as a regulator ofmacro-
phage inﬂammatory responses [37]. To investigate the cellular mecha-
nisms underlying our in vivo ﬁndings, we analyzed whether CO-
dependent reduction of miR-34a may regulate inﬂammatory responses
through SIRT1 induction in vitro. We ﬁrst examined the effect of CO on
SIRT1 expression in vitro using Kupffer cells, RAW 264.7 macrophages,
and mouse AML12 hepatocytes. After culture of KCs, more than 90% of
cells were F4/80-positive macrophages (Supplementary Fig. 2A).
When macrophages or hepatocytes were incubated with the CO donor
compound CORM-2, SIRT1 expression increased in a dose-dependent
manner (Supplementary Fig. 2B). LPS treatment increased miR-34a ex-
pression in KCs (Fig. 3A) or RAW 264.7 cells (Supplementary Fig. 3A),
which in turn was decreased profoundly in the presence of the CO-
releasing molecule (CORM2). We investigated the effect of CORM2 on
the acetylation of NF-κB/p65 in response to LPS treatment. In agreement
with our in vivo data, analysis revealed that treatment with CORM2 sig-
niﬁcantly increased the protein and mRNA levels of SIRT1 and de-
creased LPS-induced acetylation of p65 in KCs (Fig. 3B, Supplementary
Fig. 4A for semi-RT PCR ) or RAW 264.7 cells (Supplementary Fig. 3B,
Supplementary Fig. 4D for semi-RT PCR). To further deﬁne the role of
SIRT1 in the regulation of inﬂammation, we quantiﬁed the expression
of several inﬂammatory genes. The miR-34a reduction elicited by
CORM2 was associated with signiﬁcant reduction of the expression of
TNF-α, IL-6, IL-1β, and iNOS, a known NF-κB target gene, in response
to LPS in KCs (Fig. 3C, Supplementary Fig. 4B for semi-RT PCR) or RAW
264.7 cells (Supplementary Fig. 3C, Supplementary Fig. 4E for semi-RT
PCR). Taken together, these data suggest that CO-mediated SIRT1 induc-
tion can negatively regulate the LPS-mediated inﬂammatory response
through deacetylation of NF-κB/p65.
3.6. SIRT1 induction via downregulation of the miR-34a signaling pathway
negatively regulates the LPS-mediated inﬂammatory response in vitro
To examine the functional consequences of SIRT1-dependent in-
ﬂammatory responses, we analyzed the cellular levels of SIRT1 in mac-
rophages treated with the p53 inhibitor PFT. As the result of PFT
Fig. 2. Administration of the p53 inhibitor, PFT ameliorates liver I/R injury by inducing SIRT1 in mice. Mice were subjected to 60 min liver warm ischemia, followed by 4 h of reperfusion.
Liver samples were harvested from unclampedmice (sham) or mice clamped and pretreated with DMSO (IR) or Piﬁthrim-α (IR-PFT). (A) Hepatocellular function was evaluated by sALT
(U/L). (B) MPO level, an index of neutrophil inﬁltration. (C) H&E staining of liver sections from each group. (D) Hepatic HMGB1 expression in liver tissue was assessed by Western blot
analysis. (E) Semi- and quantitative RT-PCR-assisted detection of TNF-α, IL-6, iNOS, CXCL10, and IL-1β gene expression in liver samples. (F) Hepatic expression of SIRT1, Ac-p65 and
p65were evaluated in IR lobes fromDMSO (IR) and PFT (PFT-IR) injectedmice versus shammice by immunoblotting. (G) SIRT1mRNA expressionwas detected by semi- and quantitative
RT-PCR in liver tissue. (H) Expression of miR-34a was evaluated in liver tissue by quantitative RT-PCR. Data shown represent the mean ± SD. (N= 4–6/group), *P b 0.05, **P b 0.01.
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264.7 cells (Supplementary Fig. 3D). LPS-stimulated cells that were
pretreated with PFT displayed a marked increase in SIRT1 protein
(Fig. 3E, upper panel) and mRNA levels (Fig. 3E, lower panel; Supple-
mentary Fig. 4C for semi-RT PCR) in KCs, or SIRT1 protein (Supplemen-
tary Fig. 3E, left) and mRNA levels (Supplementary Fig. 3E, right;
Supplementary Fig. 4F for semi-RT PCR) in RAW 264.7 cells, whereas
the LPS-induced acetylation of p65 was markedly decreased in KCs
(Fig. 3E) or RAW 264.7 cells (Supplementary Fig. 3E). To further deﬁne
the role of SIRT1 in the regulation of inﬂammation, we quantiﬁed the
mRNA levels of several inﬂammatory genes in response to LPS in the ab-
sence or presence of PFT treatment. The inhibition of p53 by PFT signif-
icantly reduced the expression of TNF-α, IL-6, and iNOS, a knownNF-κB
target gene, in response to LPS in KCs (Supplementary Fig. 5A for semi-
RT PCR; Supplementary Fig. 5B for quantitative RT-PCR) or RAW 264.7
(Supplementary Fig. 5C for semi-RT PCR; Supplementary Fig. 5D for
quantitative RT-PCR). Together, these data show that p53 inhibition
by PFT can negatively regulate the LPS-mediated inﬂammatory re-
sponse in vitro. To conﬁrm the SIRT1-dependent anti-inﬂammatory
mechanism induced by PFT, we silenced SIRT1 by siRNA transfection.
SIRT1 knockdown signiﬁcantly decreased SIRT1 mRNA levels in RAW264.7 cells (Fig. 3F and G; Supplementary Fig. 4G for semi-RT PCR).
SIRT1 knockdown blunted the inhibitory effect of PFT on the acetylation
of p65 induced by LPS. These data suggest that the effect of PFT on p65
deacetylation is mediated by SIRT1 induction (Fig. 3H). SIRT1 knock-
down also reversed the inhibitory effect of PFT on LPS-induced expres-
sion of iNOS and pro-inﬂammatory cytokines such as TNF-α, IL-6, and
IL-1β (Fig. 3I and Supplementary Fig. 4H for semi-RT PCR). These data
indicate that the inhibition of the p53/miR-34a axis resulting in en-
hanced SIRT1 signaling can negatively regulate inﬂammatory responses
in macrophages in part through p65 deacetylation.
3.7. CO inhibits miR-34a resulting in SIRT1-dependent inhibition of p53 ac-
tivity in hepatocytes
To characterize the effect of CORM in modulating miR-34a expres-
sion, we transfected AML12 hepatocytes with a miR-34a mimic, in the
presence or absence of CORM2. The miR-34a expression was markedly
increased compared with the miR-control. CORM2 dose-dependently
reduced the level of miR-34a in miR-34a transfected cells (Fig. 4A). In
addition, miR-34a overexpression led to a 2-fold decrease in SIRT1 ex-
pression (Fig. 4B). Notably, the reduction in SIRT1 expression induced
Fig. 3. The protective effect of p53 inhibition by COor PFT is dependent on themiR-34a/SIRT1 pathway. (A–C)Kupffer cells (KCs)were stimulatedwith 1 μg/ml of LPS for 3 h in the absence
or presence of CORM2 (20 μM). A. The level of miR-34awas evaluated by quantitative RT-PCR. B. Cell lysateswere analyzed byWestern blotting with antibodies against SIRT1, acetylated-
p65, p65, or β-actin (upper panel). SIRT1 mRNA expression was also evaluated by quantitative RT-PCR (lower panel). C. The gene expression of TNF-α, IL-6, iNOS, and IL-1βwas evaluated
by quantitative RT-PCR. (D and E) KCs were stimulated with 1 μg/ml of LPS for 3 h in the absence or presence of PFT (10 μM). D. The level of miR-34awas determined by quantitative RT-
PCR. E. SIRT1, acetylated-p65, p65, orβ-actinwasmeasured by immunoblotting (upper panel). SIRT1mRNA expressionwas alsomeasuredbyquantitative RT-PCR (lower panel). (F–I) RAW
264.7 cellswere transfectedwith SIRT1-speciﬁc siRNA (siSIRT1) or scrambled siRNA (scRNA). After 48 h, cells were stimulatedwith 1 μg/ml of LPS for 3 h in the absence or presence of PFT.
Total RNAwas collected for assessment of transcription levels by (F and G, SIRT1; I, TNF-α, IL-6, iNOS, and IL-1β) quantitative RT-PCR and level of acetylated-p65 and p65 were measured
by (H) Western blotting. Data shown represent the mean ± SD. (N = 3), *P b 0.05. **P b 0.01, ***P b 0.001.
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data suggest that CO protects the liver by inducing SIRT1 expression
by downregulating the p53/miR-34a pathway. To examine whether
the modulation of SIRT1 by CORM2 occurs via miR-34a, we co-
transfected cells with a luciferase reporter construct containing the
miR-34a binding site within the SIRT1 3′UTR (Luc-SIRT1 3′UTR) togeth-
er with a miR-34a mimic. While miR-34a overexpression led to a de-
crease in luciferase activity, CORM2 treatment resulted in increasedluciferase activity in both control and miR-34a overexpressing cells
(Fig. 4C). To further investigate whether CO can affect p53 transcrip-
tional activity, we assessed p53 transactivation in cells overexpressing
p53, in the presence or absence of CORM2 (Fig. 4D). While p53 overex-
pression increased p53 transcriptional activity approximately 5-fold,
treatmentwith CORM2 signiﬁcantly inhibited p53 transcriptional activ-
ity. These data suggest that p53 is a key molecular target of CORM2 in
modulating hepatic I/R injury. To further evaluate the role of CO in
Fig. 4. Carbon monoxide inhibits p53-dependent induction of the miR-34a/SIRT1/p53 pathway in hepatocytes. (A and B) AML12 hepatocytes were transfected with control miRNA
(miRCTL) or mimic miR-34a for 48 h and then treated with CORM2. A. the level of miR-34a was evaluated by quantitative RT-PCR. B. The levels of SIRT1 and β-actin were measured by
western blotting. (C) AML12 hepatocytes were co-transfected with SIRT1 3’UTR luciferase constructs and control miRNA (miRCTL) or mimic miR-34a for 48 h and then treated with
CORM2 (20 μM). Cells were harvested and luciferase activity was determined. (D) AML12 hepatocytes were co-transfected with p53 responsive element reporter constructs (p53-luc)
and p53 expressing plasmids for 48 h and then treated with CORM2 (20 μM). Cells were lysed and assayed for luciferase activity. (E and F) AML12 hepatocytes were transfected with
p53 expressing plasmid for 48 h and treated with CORM2. E. Expression of miR-34a was evaluated by quantitative RT-PCR. F. The level of SIRT1 was measured by quantitative RT-PCR
(upper panel) and western blotting (lower panel). (G) AML12 hepatocytes were transfected with p53 responsive element reporter constructs (p53-luc) for 36 h. Cells were pretreated
with CORM2 and stimulated with 0.2 mM of H2O2. After 6 h, luciferase activity was measured. The levels of ﬁreﬂy luciferase activity were normalized to Renilla luciferase activity.
(H) AML12 hepatocytes were pretreated with CORM2 and stimulated with 1 mM of H2O2. Expression of miR-34a was evaluated by quantitative RT-PCR. (I) Primary Hepatocytes were
pretreated with CORM2 and incubated with 1 mM of H2O2 for 6 h. The levels of SIRT1, ac-p53, and β-actin were measured by western blotting. (J) Primary hepatocytes were transfected
with siSIRT1 or scRNA. After 48 h, cells were pretreated with or without the indicated SIRT1 inhibitor (EX527; 10 μM) for 1 h, followed by treatment with CORM2 (20 μM) alone or in
combination for 1 h and harvest after incubating with H2O2 (1 mM) for 6 h. The levels of SIRT1, acetylated-p53, cleaved caspase-3, Bax, and β-actin were measured by western blotting.
Data shown represent the mean ± SD. (N = 3), *P b 0.05. **P b 0.01, ***P b 0.001.
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p53 expression vector. Overexpression of p53 led to a 1.3-fold increase
in miR-34a expression compared to empty vector-transfected cells. Im-
portantly, CORM2 abrogated the induction of miR-34a by p53 expres-
sion (Fig. 4E). Consistently, p53 overexpression also decreased SIRT1mRNA and protein levels, an effect reversed by CORM2 (Fig. 4F). Be-
cause hepatic I/R injury is characterized by the generation of reactive
oxygen species (ROS), such as superoxide anion and H2O2, we utilized
H2O2-mediated oxidant injury as an in vitromodel of reperfusion injury.
To determine the functional signiﬁcance of the p53/miR-34a/SIRT1
1558 H.J. Kim et al. / Biochimica et Biophysica Acta 1852 (2015) 1550–1559pathway and its regulation by CO in vitro, we analyzedp53 expression in
H2O2-challenged AML12 hepatocytes treated with the CO donor com-
pound CORM2. Treatment with H2O2 increased p53 gene expression
and accumulation. As expected, CORM2 decreased p53 transcriptional
activity in a dose-dependent manner (Fig. 4G). To investigate the effect
of CORM2 on the apoptotic response of AML12 hepatocytes, we induced
oxidative stress using H2O2. In these cells, miR-34a expression was in-
creased by H2O2; whereas, it was reduced by CORM2 (Fig. 4H). In addi-
tion, CORM2 also efﬁciently reduced H2O2-dependent p53 acetylation
through SIRT1 induction in primary hepatocytes (Fig. 4I) or AML12
cells (Supplementary Fig. 5A). Silencing of SIRT1 in H2O2 and CORM-
treated primary hepatocytes (Fig. 4J) or AML12 cells (Supplementary
Fig. 6B) reversed the CO-dependent reduction of cleaved caspase-3,
p53 acetylation, and Bax expression. This data suggest that silencing of
SIRT1 attenuated the anti-apoptotic functions of CORM through increas-
ing p53 acetylation.
4. Discussion
In the current study, we have identiﬁed SIRT1 as a novel therapeutic
target of the anti-inﬂammatory effect of CO, a candidate therapeutic gas,
in a hepatic I/R injury model. We demonstrated that induction of SIRT1
in the liver after CO inhalation resulted in protection in a hepatic I/R
model. CO, which can be applied by inhalation or by pharmacological
delivery using CORMs, continues to show promise as an anti-
inﬂammatory therapeutic in several models of organ I/R injury [38].
For example, inhaled CO conferred tissue protection in rodents subject-
ed to lung I/R injury, as evidenced by reduced markers of apoptosis,
which depended on the activation of the MKK3/p38 MAPK pathway
[13,14]. An additional mechanism for CO-mediated protection during
lung I/R involves downregulation of the pro-inﬂammatory transcription
factor Egr-1 [32]. Several studies demonstrated that pretreatment with
CO donor compounds can ameliorate liver transplant-associated I/R in-
jury through increased hepatic HSP70 expression [39], and suppression
of inﬂammatory responses via downregulation of the MEK/ERK1/2 sig-
naling pathways [40]. Hepatic I/R injury can be attributed to the inﬁltra-
tion of immune cells and to apoptosis of liver cells. Importantly, we
found that CO reduced the inﬂammatory response by preventing the in-
ﬁltration of immune cells (Fig. 1D, E). Consistent on our results, CO has
also been shown to protect against acute liver injury caused by TNF-α
challenge in rodent models [41], and can confer anti-inﬂammatory pro-
tection in hepatic I/R injury models [8,11,12,40]. CO preserved hepatic
function ex vivo in an isolated perfused liver model subjected to cold is-
chemia injury, in part by upregulating the p38 MAPK pathway [11]. CO
has also been shown to protect against I/R injury during orthotropic rat
liver transplantation by downregulating pro-inﬂammatory mediators,
including TNF-α and iNOS expression [40]. Furthermore, the protection
afforded by CO in thismodel was also associatedwith themodulation of
STAT1/STAT3 and inhibition of the MEK/ERK1/2 signaling pathway [8].
HO-1-derived CO can reduce expression of miR-34a to improve the sur-
vival of myoblasts after intramuscular transplantation [34]. Based on
our data, we suggest a novel mechanism bywhich COmitigates murine
hepatic I/R injury via the induction of SIRT1 (Fig. 1F). SIRT1 is a cytosolic
deacetylase that can catalyze the deacetylation of histones and other
substrates such as p53 and NF-κB [42,43]. The organ protection con-
ferred by CO-dependent SIRT1 activationwas associatedwith downreg-
ulation of the inﬂammatory response, involving increased NF-κB and
p53 deacetylation, and inhibition of pro-inﬂammatorymediators. Previ-
ous studies have demonstrated that knockdown of SIRT1 can result in
enhanced activation of LPS-stimulated NF-κB activation and expression
of pro-inﬂammatory cytokines such as TNF-α, IL-1β, and IL-6 [23].
Deacetylation of p53 by SIRT1 can reduce apoptosis in the heart and kid-
ney [44–47]. SIRT1 has also been shown to protect the heart and brain
from I/R injury [24,25], and can lead to attenuated inﬂammation and ap-
optosis through NF-κB and p53 deacetylation. To date, no studies have
assessed the role of SIRT1 in hepatic I/R injury. Therefore, we suggestthat the induction of SIRT1 by CO can alleviate inﬂammation and apo-
ptosis via p65 deacetylation (Fig. 3) and via p53 deacetylation (Fig. 4).
We also demonstrate for theﬁrst time that the increase of SIRT1 expres-
sion by CO is regulated by miR-34a in the liver (Fig. 4). CO also rescued
SIRT1 expression in p53 or miR-34a overexpressing cells. Consistent
with our results, SIRT1 expression in the liver is suppressed by miR-
34a [26,27] through amiR-34a binding site that occurs in the 3′ untrans-
lated region (UTR) of SIRT1. ThemiR-34a-dependent downregulation of
SIRT1 leads to an increase in acetylated p53 and increased expression of
p21 and PUMA, transcriptional targets of p53 that regulate the cell cycle
and apoptosis, respectively, ultimately causing apoptosis [27]. Recently,
it has been reported that targeting of the miR-34a/SIRT1/p53 pro-
apoptotic pathway in primary hepatocytes results in increased SIRT1
expression, decreased acetylation of p53, and reduced apoptosis [28,29].
In summary, our results establish a signaling pathway by which CO
can confer anti-inﬂammatory protection in the liver. CO downregulates
miR-34awhich results in the activation of the SIRT1deacetylase, leading
to the deacetylation of NF-κB/p65 and p53, and downmodulation of
pro-inﬂammatory gene expression. Our results further validate the po-
tential use of CO as a pharmacological cytoprotective agent against he-
patic I/R injury, and identify miR-34a/ SIRT1 as a major therapeutic
target of CO action in the liver.
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